In a regulatory filing, Lucid Diagnostics (LUCD) disclosed that its director Dennis Matheis bought 350K shares of common stock as part of option exercise on May 20th in a total transaction size of $457.6K.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics files to sell 36.98M shares of common stock for holders
- Lucid Diagnostics Reports Increased Losses Amid Revenue Decline
- Anticipated Medicare Coverage and Strategic Positioning Drive Buy Rating for Lucid Diagnostics
- Lucid Diagnostics: Strong Cash Position and Growing EsoGuard Test Volumes Justify Buy Rating
- Lucid Diagnostics Reports Q1 2025 Financial Results